Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Variation in the Binding of 125I-labeled Interferon-βser to Cellular Receptors during Growth of Human Renal and Bladder Carcinoma Cells in Vitro

Frank J. Ruzicka, Steven M. Schmid, Debra S. Groveman, Kenneth B. Cummings and Ernest C. Borden
Frank J. Ruzicka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Schmid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra S. Groveman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth B. Cummings
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernest C. Borden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 1987
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Studies of various established human bladder and renal carcinoma cell lines cultured in vitro demonstrated the presence of specific, saturable, high affinity binding sites for 125I-labeled human interferon βser (IFN-βser). This recombinant produced interferon labeled with approximately one atom of 125I/molecule of IFN expressed minimal or no loss of antiviral activity. A single class of binding sites (1000–2000/cell) with an affinity constant of 1010–1011 L/M was measured at 4°C for cells exhibiting widely different sensitivity to the antiproliferative effect of IFN-βser. Major fluctuations in the binding of 125I-labeled IFN-βser to cellular receptors were observed during in vitro proliferation of four of five cell lines examined. A significant decrease (P < 0.001) in specific binding was observed 48 h after cultures were established. Cell cycle analysis suggested that within the first 24 h and in the very late log and stationary phase of growth of ACHN (human renal carcinoma) cells, variations in the binding of 125I-labeled IFN-βser were partially attributable to binding fluctuations during the mitotic cycle. The 2- to 3-fold decline 24 h following plating of ACHN cells corresponded to a 70% decrease in the number of cells in G0-G1. T24 (human transitional cell carcinoma) and ACHN cells, synchronized by serum starvation, demonstrated increased binding of 125I-labeled IFN-βser 4–16 h following serum replenishment. This increase in receptor binding occurred prior to the onset of DNA and protein synthesis and was followed by a decline immediately prior to cell division. Binding site analysis indicated that the increased binding prior to DNA synthesis was due to a 5- to 6-fold increase in receptor affinity for the radiolabeled ligand. After an initial 40% decline in receptors per cell following serum stimulation, receptor concentration remained essentially unchanged. Induction of 2′,5′-oligoadenylate synthetase in ACHN cells and antiproliferative activity in RT112, RT4, T24 (human transitional cell carcinoma), and ACHN cells by IFN-βser decreased significantly 48 h following plating. These changes in the biological activity of this interferon corresponded to growth related fluctuations in the IFN-βser binding.

Footnotes

  • ↵1 Supported by the Triton Biosciences Interferon Program (Alameda, CA).

  • ↵2 Recipient of a NIH National Research Service Award Supported Postdoctoral Fellowship.

  • ↵3 American Cancer Society Professor of Clinical Oncology. To whom requests for reprints should be addressed.

  • Received October 27, 1986.
  • Revision received May 27, 1987.
  • Accepted June 3, 1987.
  • ©1987 American Association for Cancer Research.
PreviousNext
Back to top
September 1987
Volume 47, Issue 17
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Variation in the Binding of 125I-labeled Interferon-βser to Cellular Receptors during Growth of Human Renal and Bladder Carcinoma Cells in Vitro
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Variation in the Binding of 125I-labeled Interferon-βser to Cellular Receptors during Growth of Human Renal and Bladder Carcinoma Cells in Vitro
Frank J. Ruzicka, Steven M. Schmid, Debra S. Groveman, Kenneth B. Cummings and Ernest C. Borden
Cancer Res September 1 1987 (47) (17) 4582-4589;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Variation in the Binding of 125I-labeled Interferon-βser to Cellular Receptors during Growth of Human Renal and Bladder Carcinoma Cells in Vitro
Frank J. Ruzicka, Steven M. Schmid, Debra S. Groveman, Kenneth B. Cummings and Ernest C. Borden
Cancer Res September 1 1987 (47) (17) 4582-4589;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates
  • Formation and Persistence of DNA Adducts of 2-Amino-3-methylimidazo[4,5-f] quinoline in Male Fischer-344 Rats
  • Effects of Recombinant α-Interferon-Gelatin Conjugate on in Vivo Murine Tumor Cell Growth
Show more Basic Sciences

Articles

  • Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates
  • Formation and Persistence of DNA Adducts of 2-Amino-3-methylimidazo[4,5-f] quinoline in Male Fischer-344 Rats
  • Effects of Recombinant α-Interferon-Gelatin Conjugate on in Vivo Murine Tumor Cell Growth
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement